A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 08 Jul 2025
At a glance
- Drugs 611-3SBio (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Sunshine Guojian Pharmaceutical
Most Recent Events
- 08 Jul 2025 New trial record